# QA Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0160 |
| PP ID | PP-0160 |
| Title | H. pylori and Gastric Cancer Prevention |
| Version | 1.0.0 |
| Status | PASS |

# Layer 1 — Content QA

| Check | Result |
|---|---|
| One atomic clinical question | PASS |
| Patient-centered scope | PASS |
| H. pylori carcinogenicity | PASS |
| Gastric-cancer prevention rationale | PASS |
| Carcinogenic pathway | PASS |
| Randomized evidence | PASS |
| Meta-analysis evidence | PASS |
| Asymptomatic prevention | PASS |
| Family-history context | PASS |
| Secondary prevention | PASS |
| Residual risk | PASS |
| Antimicrobial stewardship | PASS |
| Patient misconceptions | PASS |
| Primary vs secondary prevention | PASS |

# Layer 2 — Clinical QA

| Check | Result |
|---|---|
| H. pylori distinguished from generic risk factors | PASS |
| H. pylori cause vs risk-factor wording preserved | PASS |
| Noncardia emphasis preserved | PASS |
| Correa-type progression kept conceptual | PASS |
| Eradication not presented as guaranteed prevention | PASS |
| Established precursor damage not described as fully reversible | PASS |
| Asymptomatic benefit represented | PASS |
| Family-history evidence represented | PASS |
| Secondary prevention represented | PASS |
| Universal test-and-treat not recommended | PASS |
| Antibiotic resistance considered | PASS |
| Exact eradication regimen excluded | PASS |

# Layer 3 — Evidence QA

| Check | Result |
|---|---|
| NCI Prevention PDQ used as primary source | PASS |
| NCI H. pylori and Cancer used as primary source | PASS |
| NCI Genetics PDQ used for precursor pathway | PASS |
| NCCN used only for limited treatment-context support | PASS |
| RCT evidence traceable | PASS |
| Meta-analysis estimate traceable | PASS |
| Family-history RCT traceable | PASS |
| Asymptomatic evidence traceable | PASS |
| Metachronous-cancer evidence traceable | PASS |
| Generalizability limitation documented | PASS |
| Resistance concern documented | PASS |
| Unsupported universal policy avoided | PASS |

# Layer 4 — Boundary / Overlap QA

## PP-0012 — Helicobacter pylori

PP-0012 owns the infection as a general clinical concept.

PP-0160 owns the cancer-prevention implication.

**Result: PASS**

## PP-0161 — H. pylori Eradication for Gastric Cancer Prevention

PP-0161 owns the eradication intervention.

PP-0160 owns the rationale and prevention evidence.

**Result: PASS**

## PP-0155 — Family History and Gastric Cancer Risk

PP-0155 owns family history as a risk factor.

PP-0160 uses family history only to contextualize prevention benefit.

**Result: PASS**

## PP-0165 — Atrophic Gastritis

PP-0165 owns detailed atrophic gastritis.

PP-0160 uses atrophy only as a downstream carcinogenic state and timing concept.

**Result: PASS**

## PP-0166 — Intestinal Metaplasia

PP-0166 owns detailed intestinal metaplasia.

PP-0160 uses it only to explain residual risk after established mucosal change.

**Result: PASS**

## PP-0170 — Gastric Cancer Screening in High-Risk Individuals

PP-0170 owns broader screening.

PP-0160 does not become a screening package.

**Result: PASS**

## PP-0162 / PP-0163 / PP-0164

Smoking, diet, and obesity remain separate risk-factor packages.

**Result: PASS**

# Layer 5 — Safety QA

| Safety Check | Result |
|---|---|
| No individualized treatment prescription | PASS |
| No universal testing recommendation invented | PASS |
| No exact antibiotic regimen included | PASS |
| No guarantee of cancer prevention | PASS |
| No claim that eradication reverses all damage | PASS |
| Antimicrobial resistance addressed | PASS |
| Population-risk generalizability caveat included | PASS |
| Secondary prevention not confused with primary prevention | PASS |

# Layer 6 — Artifact QA

| Artifact | Status |
|---|---|
| 01_CKO.md | PASS |
| 02_KNOWLEDGE_PASSPORT.md | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS |
| 04_QA_REPORT.md | PASS |

# Layer 7 — Governance QA

The package follows the locked Gold workflow:

- Source-First verification;
- approved/locked Decision Batch;
- atomic scope;
- adjacent-PP overlap control;
- four-artifact Gold structure;
- evidence-level distinction;
- explicit boundary/delegation.

The PP Registry places PP-0160 immediately before PP-0161, followed by separate smoking, diet, obesity, atrophic gastritis, intestinal metaplasia, pernicious anemia, EBV, adenoma, and high-risk screening packages. fileciteturn29file3

**Governance result: PASS**

# Final QA Decision

**PASS**

PP-0160 is clinically coherent, source-grounded, atomic, patient-centered, and clearly separated from PP-0012 and PP-0161.

# Final Status

**PASS — GOLD — READY FOR INTEGRATION**
